CGTX
Cognition Therapeutics, Inc.·Healthcare
1.19
4.032%(−0.05)
Close PriceLast Updated: — ET
52W L: $0.2252W H: $3.83
CGTX NEWS
globenewswire.com
6d ago
Cognition Therapeutics Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies with Psychosis
- Positive Discussion on Path Forward for Registrational Program - PURCHASE, N.Y., May 21, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), conducted a planned meeting with the U.S. Food and Drug Administration (FDA) on May 20, 2026.
globenewswire.com
May 14
Cognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
PURCHASE, N.Y., May 14, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that a second philanthropic donation has been received from a participant in the ongoing expanded access program (EAP) for people with dementia with Lewy bodies (DLB). The ongoing EAP has been extended to provide two years of treatment for participants, thanks to a generous new donation from Mr. Jeffrey Pechter, founding partner of Mindful Capital in Delray Beach, FL.
globenewswire.com
May 7
Cognition Therapeutics Reports Financial Results for the First Quarter 2026 and Provides Business Update
Meeting with FDA Division of Psychiatry scheduled for May 2026 expected to inform registrational plans for zervimesine in DLB psychosis PURCHASE, N.Y., May 07, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), clinical-stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), today reported financial results for the first quarter ended March 31, 2026, and provided a business update.
defenseworld.net
Apr 21
Cognition Therapeutics (NASDAQ:CGTX) CEO Lisa Ricciardi Acquires 9,175 Shares of Stock
Cognition Therapeutics, Inc. (NASDAQ: CGTX - Get Free Report) CEO Lisa Ricciardi bought 9,175 shares of the stock in a transaction that occurred on Thursday, April 16th. The stock was bought at an average cost of $1.10 per share, for a total transaction of $10,092.50. Following the completion of the purchase, the chief executive officer directly
defenseworld.net
Apr 21
Cognition Therapeutics (NASDAQ:CGTX) CFO John Brendan Doyle Buys 10,000 Shares
Cognition Therapeutics, Inc. (NASDAQ: CGTX - Get Free Report) CFO John Brendan Doyle acquired 10,000 shares of the firm's stock in a transaction that occurred on Thursday, April 16th. The shares were bought at an average price of $1.13 per share, with a total value of $11,300.00. Following the completion of the purchase, the chief financial
defenseworld.net
Apr 15
Cognition Therapeutics Targets Faster DLB Psychosis Path as Zervimesine Nears Late-Stage Plans
Cognition Therapeutics (NASDAQ: CGTX) executives told investors at the Needham conference that the company is preparing to advance its once-daily oral candidate zervimesine into late-stage development, with an initial focus on psychosis symptoms in dementia with Lewy bodies (DLB) while continuing to run a large National Institute on Aging (NIA)-funded Alzheimer's disease study. Pipeline focus shifts
